Hence, we aimed to assess the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with stage IIIB/IV NSCLC harbouring EGFR mutations (exon 19 deletion or exon 21 L858R mutation) in The Netherlands from a Dutch societal perspective. This evidence concerns the gene EGFR and non-small cell lung carcinoma.